Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GAO Memory Supplement Review Recalls FDA's Regulatory Challenges

This article is powered by The Rose Sheet

Executive Summary

GAO recommends better cooperation between FDA and FTC and more public outreach are key to preventing consumers from believing noncompliant cognitive benefit claims for supplements.


Related Content

Yohimbe Ban Suggested, 'God' Warned: Health And Wellness Industry News
Industry Eyes NDI Notification Common Ground With Gottlieb-Led FDA
FTC Enforcement Hangs Over Memory Product Firm After Overlooking NAD Review
New York AG And FTC Target Prevagen Memory Claims
FDA Guidance Makes Vinpocetine Compliant Despite Ban Proposal – NPA
Sen. McCaskill Reaches Out To Retailers On Picamilon ‘In The Absence Of FDA Action’
Homeopathic Claims Pose Continuing FTC/FDA Regulatory Conflict
Congress Says GAO Report Supports Increasing Supplement Oversight





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts